BRIEF published on 12/11/2024 at 07:34, 10 days 7 hours ago Evotec SE and Novo Nordisk Launch LAB eN² Projects for Drug Discovery Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
PRESS RELEASE published on 12/11/2024 at 07:29, 10 days 7 hours ago Evotec SE announces first projects for LAB eN² drug discovery accelerator with Novo Nordisk Evotec SE announces selection of first projects for LAB eN² drug discovery accelerator with Novo Nordisk, focusing on cardiometabolic diseases from academic institutions Drug Discovery Evotec SE Novo Nordisk Cardiometabolic Diseases LAB EN²
BRIEF published on 11/29/2024 at 07:36, 22 days 7 hours ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
PRESS RELEASE published on 11/29/2024 at 07:31, 22 days 7 hours ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 28 days 22 hours ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
PRESS RELEASE published on 11/22/2024 at 16:55, 28 days 22 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 month 6 days ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
PRESS RELEASE published on 11/14/2024 at 22:51, 1 month 6 days ago EQS-Adhoc: Comment on media report Evotec SE receives non-binding expression of interest from Halozyme Therapeutics Inc. for a takeover offer of EUR 11.00 per share Evotec SE Takeover Offer Expression Of Interest Halozyme Therapeutics Inc. EUR 11.00 Per Share
BRIEF published on 11/06/2024 at 07:05, 1 month 15 days ago Evotec SE Reports Strategic Progress and Revenue Growth Amid Challenges Strategic Partnerships 2024 Forecasts Biologics Growth Evotec Financial Results Priority Reset Initiative
PRESS RELEASE published on 11/06/2024 at 07:00, 1 month 15 days ago Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions Evotec SE reports 9M 2024 results with strategic progress amid challenging market conditions. New partnerships and operational milestones achieved Financial Results Evotec SE Partnerships 9M 2024 Operational Milestones
Published on 12/21/2024 at 01:30, 13 hours 52 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 13 hours 52 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 15 hours 17 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 15 hours 52 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 14 hours 30 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 14 hours 37 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 20 hours 11 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 20 hours 26 minutes ago CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 21 hours 22 minutes ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 3 hours 4 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 21 hours 22 minutes ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 21 hours 27 minutes ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 1 hour ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 1 day 20 hours ago Share capital decrease by way of treasury shares cancellation
